Research and Markets: Hypertrophic Cardiomyopathy Therapeutics Market Report - Global Industry Analysis and Forecast 2015-2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/v7zcsk/hypertrophic) has announced the addition of the "Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023" report to their offering.

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis.

A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.

The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Major players profiled include:

  • AstraZeneca plc
  • Concordia Healthcare Corp.
  • Sanofi S.A.
  • Pfizer, Inc.
  • Merck & Co.
  • Inc., Teva Pharmaceuticals Limited
  • Mylan N.V.
  • Gilead Sciences, Inc.
  • Novartis AG

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class:

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Antiarrhythmic Agents
  • Anticoagulants

Key Topics Covered:

1. Preface

2. Executive Summary

3. Hypertrophic Cardiomyopathy Therapeutics Market - Industry Analysis

4. Market Segmentation - By Drug

6. Market Segmentation - By Geography

7. Recommendations

For more information visit http://www.researchandmarkets.com/research/v7zcsk/hypertrophic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular